Log In
Print
BCIQ
Print
Print this Print this
 

HyNap nilotinib

  Manage Alerts
Collapse Summary General Information
Company XSpray Microparticles AB
DescriptionFormulation of nilotinib, a BCR-ABL tyrosine kinase inhibitor, using XSpray's HyNap hybrid nanoparticle technology
Molecular Target BCR-ABL tyrosine kinase
Mechanism of ActionBCR-ABL tyrosine kinase inhibitor
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase I
Standard Indication Cancer (unspecified)
Indication DetailsTreat cancer
Regulatory Designation

Partner


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today